Jakafi Improves Symptoms, Spleen Volume in Myelofibrosis
Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed.
Educated Patient® MPN Summit ET Risk Stratification Presentation: May 20, 2023
Watch Dr. Lucia Masarova, from MD Anderson Cancer Center, discuss risk stratifying patients with essential thrombocythemia during the CURE® Educated Patient® MPN Summit.
Maintenance Darzalex Regimen Promising in Post-Transplant Myeloma
Maintenance Darzalex, with or without Pomalyst was safe and efficacious in treating patients with relapsed myeloma who underwent salvage autologous hematopoietic stem cell transplant.
Iclusig With Chemo ‘Should Be Standard of Care’ for ALL Subset
Iclusig plus reduced-intensity chemotherapy led to improved outcomes for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia, and should be the new standard of care, one expert said.
Study Examines Calquence in Older CLL Population
An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.
ctDNA May Help Predict Lung Cancer Outcomes, Guide Treatment
Patients with non-small cell lung cancer who cleared 50% or more of cancerous DNA from their blood by their fourth treatment cycle tended to have better outcomes on maintenance therapy, research showed.
Maintenance Zejula Induces Antitumor Activity, Increases Survival in Advanced Ovarian Cancer
Meaningful improvements in survival were obtained with Zejula maintenance therapy compared with placebo in patients with advanced ovarian cancer that was newly diagnosed.
Tumor Treating Fields With Standard of Care May Significantly Improve Survival in Metastatic NSCLC
Tumor treating fields therapy “is a potentially paradigm-shifting new treatment modality” for metastatic non-small cell lung cancer, says Dr. Ticiana Leal.
Adding Opdivo to Chemo May Prolong Survival in Advanced Hodgkin Lymphoma
Patients with advanced-stage classic Hodgkin lymphoma had a longer progression-free survival rate with Opdivo plus AVD, a chemotherapy regimen, compared with Adcetris plus AVD.
Enhertu Is Promising for Difficult-to-Treat Solid Cancers
Adding Jemperli to Chemo Lengthens Time to Progression in Early Endometrial Cancer
Jemperli plus carboplatin and paclitaxel also helped patients with early endometrial cancer maintain their health-related quality of life throughout follow-up.
HER3-Directed Therapy Was Effective and Safe in Breast Cancer Subtype
Patients with ER-positive, triple-negative metastatic breast cancer treated with a HER3-direct antibody drug conjugate obtained clinical responses with a positive safety profile.
Survival Benefit With Lenvima/Keytruda for Advanced Clear Cell RCC Continues After 4 Years
After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.
Lenvima Plus Keytruda ‘Stood the Test of Time’ for Kidney Cancer
Longer follow-up data showed that Lenvima plus Keytruda still outperformed Sutent in the treatment of patients with advanced renal cell carcinoma.
Presurgical FOLFOX/Chemo as Effective as Chemoradiation in Rectal Cancer
Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.
Triplet Regimen Bests Single-Agent Cabometyx in Soft Tissue Sarcoma
Adding Opdivo and Yervoy to Cabometyx led to improved progression-free survival and disease control rates in patients with soft tissue sarcoma, recent research showed.
Vorasidenib May ‘Change the Treatment Paradigm’ for Low-Grade Glioma
Vorasidenib reduced the risk of disease progression or death for certain patients with low-grade brain cancer, recent study results showed.
Side Effects Manageable From Talzenna/Xtandi Treatment in Prostate Cancer Subset
Side effects such as anemia and other blood-related events were resolved with dose reductions and/or supportive care in men with metastatic castration-resistant prostate cancer.
Elranatamab Elicits Early, Deep Responses in Relapsed/Refractory Myeloma
Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.
Verzenio Dose Reductions Don’t Worsen Breast Cancer Outcomes for Older Patients
It may be more beneficial to reduce the dose of Verzenio rather than stop the drug altogether, according to the monarchE trial findings.
Three-Drug Regimen Is Promising Across Kidney Cancer Subtypes
Cabometyx, Opdivo and Yervoy led to high disease control rates across different subgroups of patients with kidney cancer, research showed.
Acupuncture Reduced Bladder Cancer Pain, Urinary Symptoms
Acupuncture reduced pain “in a very significant way” and urinary symptoms for patients with non-muscle invasive bladder cancer who were undergoing BCG therapy.
Welireg Plus Lenvima Has ‘Promising Antitumor Activity’ in Kidney Cancer Subset
Nearly three-fourths of patients with clear cell renal cell carcinoma had a disease response lasting 12 months or longer after being treated with Welireg and Lenvima, study data showed.
Pre- and Post-Surgical Keytruda Boosts Outcomes in Early NSCLC
Adding Keytruda to pre-surgical chemotherapy then giving it again after surgery improved event-free survival and pathologic complete response in patients with early-stage lung cancer.
An App Improved Anxiety, Depression Symptoms in Patients With Cancer
Participants in the RESTORE study, results of which were presented this weekend at ASCO, saw “significant improvements” in depression and anxiety symptoms after using the Attune app.
Imjudo-Imfinzi Regimen Improves Survival With Manageable Side Effects in Liver Cancer Subset
Patients with unresectable hepatocellular carcinoma treated with the STRIDE regimen, consisting of Imjudo and Imfinzi, experienced manageable immune-related side effects with improvements in overall survival.
Patients with HR+, HER2–, Early Breast Cancer Experienced Survival Improvement with Verzenio Plus Endocrine Therapy
Findings from the monarchE trial presented at ASCO showed that for patients with hormone receptor–positive, HER2-negative, high-risk, early breast cancer, Verzenio provided “consistent treatment benefit.”
Radium-223 Safe and Effective to Treat Metastatic Castration-Resistant Prostate Cancer
Treating patients with metastatic castration-resistant prostate cancer with radium-223 also allowed patients to receive subsequent therapies such as chemotherapy.
After Approval, Tecartus Continues to Impress in B-Cell ALL
The CAR-T cell therapy, Tecartus, improved outcomes for patients with B-cell acute lymphoblastic leukemia, offering a promising standard of care for this patient population.
Avastin Regimen Improves Survival in Ovarian Cancer, Including Some HRD-Positive Tumors
A progression-free survival benefit was observed in patients with advanced ovarian cancer including those with homologous recombination deficient-positive status who were treated with frontline chemo plus Avastin and Imfinzi followed by maintenance therapy with an Avastin regimen.
2 Clarke Drive Cranbury, NJ 08512